GIBTULIO (empagliflozin), GIBTULIO MET (empagliflozin + metformin) and AJADUO (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose cotransporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease.
Lupin has been marketing GIBTULIO and GIBTULIO MET since 2016, and AJADUO since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year.
Nilesh Gupta, managing director, Lupin, said, “Lupin has always been at the forefront of providing best-in-class quality healthcare solutions to patients. This acquisition is a key step in strengthening our diabetes portfolio and reaffirms our commitment to delivering innovative and cost-effective medications for patients across India.”
Rajeev Sibal, President – India Region Formulations, Lupin said, “The increasing prevalence of diabetes and related lifestyle diseases calls for greater thrust on diabetes treatment and management, as well as accessibility of medicines for patients. This acquisition enables us to deliver effective and affordable treatment options to millions across India.”
Lupin’s consolidated net profit jumped 74.1% to Rs 852.63 crore on 11.3% increase in sales to Rs 5,497.01 crore in Q2 FY25 over Q2 FY24.
The counter declined 1.95% to settle at Rs 2,075 on Friday, 13 December 2024